Technology Solutions

Pricentric ONE

Powerful Insights, timely and accurate  competitor data you can trust. 

More than just data, Pricentric ONE is the industry’s most comprehensive database of global pricing and market access intelligence, with everything you need in a single platform. 

Follow our showcase page on LinkedIn!

Global Pricing & Market Access

Everything You Need in a Single Consolidated Environment

Strategy Supported with the Right Data

Pricentric ONE by EVERSANA is a unique, powerful, comprehensive global pharmaceutical pricing and reimbursement database portal. It empowers you with the information you need to ensure your pricing strategies are on target, and allows you to monitor competitors’ responses to price actions taken for your products.

The Pricentric ONE data solution features:

  • Global Data Service – Pharmaceutical pricing strategies derived from dependable sources around the global, tracking 80+ worldwide markets including US Red Book
  • Reimbursement Data – Indication level reimbursement data for key global markets, including product reimbursement status, reimbursement amounts and patient co-pay levels
  • Cost of Treatment Calculator allows users to compare costs across therapies and indication levels
  • Latest News – Pricing and reimbursement newsletters track key deployments in pricing, reimbursement, market access and HEOR
  • Special Reports – Based on data analysis and strategic evaluation
  • Analysis Beyond Data – Full access to knowledgeable data analysts

Featured Content

At the COVID-19 Finish Line, How Do We Price The Winning Vaccine?

As of August 21, 2020, there were more than 165 potential vaccine candidates in development for the novel coronavirus. While some are still in preclinical stages, a handful are quickly making their way toward regulatory approval, meaning that pricing is starting to become an urgent reality. The first safety trials in humans started as early […]

Is BeNeLuxA Equipped for a Zolgensma Assessment?

The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in May. Belgium, Ireland, and the Netherlands will undertake a joint health technology assessment (HTA) of Zolgensma as part of […]

Contact Us

  • This field is for validation purposes and should be left unchanged.